Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb23104 · 1 trial · 16 indications
Safety and tolerability
| Arm | Type | Description |
|---|---|---|
| XmAb®23104 Monotherapy | EXPERIMENTAL | XmAb®23104 administered by IV dosing on Days 1 and 15 of each 28-day cycle x 2 cycles |
| XmAb®23104 Combination Therapy with Ipilimumab | EXPERIMENTAL | XmAb®23104 administered by IV on Days 1 and 15 of each 28-day cycle x 2 cycles + Yervoy® (ipilimumab) |
| Name | Type | Description |
|---|---|---|
| XmAb®23104 | BIOLOGICAL | Monoclonal bispecific antibody |
| Yervoy® (ipilimumab) | BIOLOGICAL | Monoclonal antibody |
Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following: 1. Melanoma (excluding uveal melanoma) 2. Cervical carcinoma 3. Pancreatic carcinoma 4...
XmAb23104 is an investigational monoclonal antibody being studied for the treatment of selected advanced solid tumors, including melanoma (excluding uveal melanoma), cervical carcinoma, pancreatic carcinoma, triple-negative breast carcinoma, hepatocellular carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, nasopharyngeal carcinoma, renal cell carcinoma, colorectal carcinoma, endometrial carcinoma, non-small cell lung carcinoma, small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, and undifferentiated pleomorphic sarcoma.
XmAb23104 is being developed by Xencor, Inc., a biopharmaceutical company traded on Nasdaq under the ticker XNCR.
XmAb23104 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA.
XmAb23104 has been studied in a Phase 1 clinical trial with the identifier NCT03752398, titled "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)." This trial was conducted in the United States and enrolled 198 participants aged 18 years and older.
Yes, the Phase 1 clinical trial of XmAb23104 (NCT03752398) was randomized and controlled, but it was not double-blinded. The trial has been completed.